Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qingdao Haier Biomedical CoSHSE:688139 +0.52%83 Return-on-Tangible-Asset is 5.74% as of Jun. 2026, which is 32% below its 10-year median of 8.41. GuruFocus rates SHSE:688139 with a GF Score™ of 83/100 and a GF Value™ of ¥37.04 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Qingdao Haier Biomedical Co ranks better than 66.27% on this metric.
The historical rank and industry rank for Qingdao Haier Biomedical Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:688139'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.39 Med: 8.41 Max: 21.82
Current: 5.52
During the past 10 years, Qingdao Haier Biomedical Co's highest Return-on-Tangible-Asset was 21.82%. The lowest was 5.39%. And the median was 8.41%.
SHSE:688139's Return-on-Tangible-Asset is ranked better than 66.27% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.96
vs SHSE:688139: 5.52
Qingdao Haier Biomedical Co (SHSE:688139) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Qingdao Haier Biomedical Co Return-on-Tangible-Asset Related Terms
Qingdao Haier Biomedical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qingdao Haier Biomedical Co Return-on-Tangible-Asset Chart
SHSE:688139 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Qingdao Haier Biomedical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qingdao Haier Biomedical Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qingdao Haier Biomedical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Qingdao Haier Biomedical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.74% mean?
Qingdao Haier Biomedical Co (SHSE:688139) has a Return-on-Tangible-Asset of 5.74% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Qingdao Haier Biomedical Co and its competitors. This is 32% below median its historical median of 8.41. Over the past decade, Qingdao Haier Biomedical Co's Return-on-Tangible-Asset has ranged from 5.39 to 21.82. According to the industry distribution chart, Qingdao Haier Biomedical Co ranks #287 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 33.7%.
Is Qingdao Haier Biomedical Co's Return-on-Tangible-Asset too high?
Qingdao Haier Biomedical Co's current Return-on-Tangible-Asset of 5.74% is 32% below median its 10-year median of 8.41. Over the past 10 years, this metric has ranged from a low of 5.39 to a high of 21.82. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.96. Qingdao Haier Biomedical Co's value of 5.74% is 497.9% above this industry median. Based on the distribution chart, Qingdao Haier Biomedical Co ranks #287 out of 851 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Qingdao Haier Biomedical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qingdao Haier Biomedical Co's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qingdao Haier Biomedical Co ranks #287 out of 851 companies for Return-on-Tangible-Asset. This puts Qingdao Haier Biomedical Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.96. Qingdao Haier Biomedical Co's value of 5.74% is 497.9% above this benchmark. Historically, Qingdao Haier Biomedical Co's own Return-on-Tangible-Asset has ranged from 5.39 to 21.82 over the past decade. While the company's 10-year median is 8.41 vs. the industry median of 0.96, Qingdao Haier Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.96, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qingdao Haier Biomedical Co's current Return-on-Tangible-Asset of 5.74% is 497.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Qingdao Haier Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qingdao Haier Biomedical Co's current Return-on-Tangible-Asset is 5.74%, which is 32% below median its own 10-year median of 8.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qingdao Haier Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co (SHSE:688139) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥37.04, compared to a current price of ¥30.80 — trading 16.8% below its estimated fair value. The current Return-on-Tangible-Asset is 5.74%, which is 32% below median its 10-year median of 8.41 and 497.9% above the Medical Devices & Instruments industry median of 0.96. Qingdao Haier Biomedical Co's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Qingdao Haier Biomedical Co (SHSE:688139), the current Return-on-Tangible-Asset is 5.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qingdao Haier Biomedical Co (SHSE:688139) Overvalued in 2026?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co stock appears to be undervalued.
The current stock price of ¥30.80 is trading 16.8% below its estimated GF Value™ of ¥37.04.
GuruFocus considers Qingdao Haier Biomedical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688139:
Return-on-Tangible-Asset: 5.74% (32% below median its 10-year median of 8.41)
GF Value™: ¥37.04 vs. price of ¥30.80 (16.8% below fair value)
Industry Position: 497.9% above the Medical Devices & Instruments median (#287 of 851)
No single metric tells the full story. See the SHSE:688139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.
83GF Score
Get the complete analysis for SHSE:688139
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688139 has been successfully added to your 
